568 results
Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction - FLOWER-MI
26 May 2021
This investigator-initiated randomised, open-label, multicentre trial compares FFR versus angiography guided strategies for treating non-culprit lesions in patients presenting with STEMI and multivessel coronary artery disease. The results of this study were released during ACC.21.
Reviewer
Reviewer
EuroPCR 2021 Hotlines / Late-Breaking Trials: MAGSTEMI, France ABSORB, FUTURE-II, STRATEGY-IT, AIDA, and PRAGUE 22
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in BRS/BVS:
- Magnesium-based Bioresorbable Scaffold in STEMI: 2 years results
- France Absorb registry: final five years follow-up
- A randomized trial of thinner-strut sirolimus-eluting BRS in de novo lesions
- Three-year follow-up of the prospective bvs stemi strategy-it study
- Final five-year results of AIDA trial
- Bioresorbable...
EuroPCR 2021 Hotlines / Late-Breaking Trials: POEM, CEL-02, and PENDULUM
21 May 2021 – From EuroPCR 2021
Find out more about various studies & registries in drugs & devices:
- POEM study: 1-month DAPT after PCI with bioresorbable-polymer EES in HBR patients
- CEL-O2 trial: a novel rapid glycoprotein IIb/IIIa inhibitor(RUC-4) for STEMI patients
- PENDULUM registry study: impact of Clinical Outcomes and Platelet Reactivity After Percutaneous Coronary
A randomised study comparing imaging guided implantation of Orsiro and Xience - CASTLE study
20 May 2021 – From EuroPCR 2021
Watch this LBT session, which was originally presented during EuroPCR 2021, to find out more about the CASTLE study, whose aim is to access the results of two types of DES implanted with image guidance in all-comers.
Paclitaxel and sirolimus coated balloons: create evidence before claims
20 May 2021 – From EuroPCR 2021
Watch this session presented by Mohd Ali Rosli, Bruno Scheller, Raban Jeger and Sylvia Otto in order to join a controversial discussion about a sirolimus and paclitaxel coated balloon approach, to follow a dedicated discussion on existing evidence on efficacy and safety for paclitaxel and sirolimus coated balloons...
Empowering DES performance in complex patients to maximise efficacy and safety outcomes
20 May 2021 – From EuroPCR 2021
Watch this session presented by Marco Valgimigli, Istvan Ferenc Edes, Antonio Colombo, Rafael Romaguera, Gennaro Sardella and Pieter Stella in order to identify the key elements and actions to be considered to maximise complex PCI outcomes in diabetes mellitus and high bleeding risks patients, to understand how re-PCI impacts...
Latest insights: when to choose orbital atherectomy
20 May 2021 – From EuroPCR 2021
Watch this session presented by Nicolas Van Mieghem, Surendra Avula and Ajay Kirtane in order to understand the challenges of treating severe calcium, to know about the OAS overview with dual-action MOA technology and the clinical evidence supporting its use, and to be introduced to treatment technique.
Sustained Limus release, redefining indications for drug-eluting balloons
20 May 2021 – From EuroPCR 2021
Watch this session presented by Bernardo Cortese, Kambis Mashayekhi, Jonas Häner and Tuomas Rissanen in order to understand how sustained Limus release technology can broaden DEB indications, to learn how SELUTION SLR sustained Limus DEB performs in daily clinical practice, and to know more about the importance of sustained Limus release technology...
Best of the European Heart Journal
19 May 2021 – From EuroPCR 2021
Watch this session, originally presented during EuroPCR 2021 by F. Crea, Editor-in-chief, and C. Berry, Executive Editor, to find out more, both about the most cited European Heart Journal original research article, and the most Almetric scored one, and enjoy in-depth analysis of the SOLVE-TAVI and DAEDALUS studies in...
Leading with evidence, latest clinical outcomes update for Firesorb, Firehawk and VitaFlow
19 May 2021 – From EuroPCR 2021
Watch this session presented by Alexandra Lansky, Andreas Baumbauch, Junbo Ge and Bo Xu in order to learn about the one-year results from a pivotal RCT (FUTURE II), the four-year results from TARGET AC, and the four-year results from VitaFlow transcatheter aortic valve system in patients with severe aortic...
